DYNE THERAPEUTICS INC (DYN)
US26818M1080 - Common Stock
Overall DYN gets a fundamental rating of 3 out of 10. We evaluated DYN against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for DYN as it has an excellent financial health rating, but there are worries on the profitability. DYN is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
DYN had negative earnings in the past year.
In the past year DYN has reported a negative cash flow from operations.
In the past 5 years DYN always reported negative net income.
DYN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
DYN has a Return On Assets (-38.31%) which is in line with its industry peers.
With a decent Return On Equity value of -41.74%, DYN is doing good in the industry, outperforming 71.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.31% | ||
| ROE | -41.74% | ||
| ROIC | N/A |
ROA(3y)-77.62%
ROA(5y)-68.06%
ROE(3y)-121.86%
ROE(5y)-97.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DYN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
DYN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DYN has been increased compared to 5 years ago.
DYN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 12.63 indicates that DYN is not in any danger for bankruptcy at the moment.
DYN has a better Altman-Z score (12.63) than 89.56% of its industry peers.
DYN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 12.63 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
DYN has a Current Ratio of 17.02. This indicates that DYN is financially healthy and has no problem in meeting its short term obligations.
DYN has a Current ratio of 17.02. This is amongst the best in the industry. DYN outperforms 91.50% of its industry peers.
DYN has a Quick Ratio of 17.02. This indicates that DYN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 17.02, DYN belongs to the best of the industry, outperforming 91.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.02 | ||
| Quick Ratio | 17.02 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 0.84% over the past year.
EPS 1Y (TTM)0.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 8.06% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y10.35%
EPS Next 2Y0.5%
EPS Next 3Y0.32%
EPS Next 5Y8.06%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
DYN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DYN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.5%
EPS Next 3Y0.32%
5. Dividend
5.1 Amount
DYN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DYNE THERAPEUTICS INC
NASDAQ:DYN (1/14/2025, 8:00:01 PM)
After market: 15 0 (0%)15
-0.29 (-1.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners111%
Inst Owner Change0%
Ins Owners0.43%
Ins Owner Change2.13%
Market Cap1.53B
Analysts86.25
Price Target51.43 (242.87%)
Short Float %10.59%
Short Ratio8.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.01%
Min EPS beat(2)-33.5%
Max EPS beat(2)3.47%
EPS beat(4)1
Avg EPS beat(4)-12%
Min EPS beat(4)-33.5%
Max EPS beat(4)3.47%
EPS beat(8)2
Avg EPS beat(8)-10.67%
EPS beat(12)4
Avg EPS beat(12)-6.48%
EPS beat(16)5
Avg EPS beat(16)-10.19%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.79%
PT rev (3m)-6.83%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-30.16%
EPS NY rev (1m)-1.57%
EPS NY rev (3m)-16.58%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.16 | ||
| P/tB | 2.16 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.56
EYN/A
EPS(NY)-3.9
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.39
OCFYN/A
SpS0
BVpS6.93
TBVpS6.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.31% | ||
| ROE | -41.74% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-77.62%
ROA(5y)-68.06%
ROE(3y)-121.86%
ROE(5y)-97.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 84.87% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 17.02 | ||
| Quick Ratio | 17.02 | ||
| Altman-Z | 12.63 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)186.14%
Cap/Depr(5y)267.05%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.03%
EPS Next Y10.35%
EPS Next 2Y0.5%
EPS Next 3Y0.32%
EPS Next 5Y8.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-46.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.7%
EBIT Next 3Y-18.55%
EBIT Next 5YN/A
FCF growth 1Y-55.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.36%
OCF growth 3YN/A
OCF growth 5YN/A